Purchase this article with an account.
Michael Peel, Andrew Scribner, Keqiang Li, Bernard Scorneaux, Sarah Mosier, Karen Polowy, Weslyn Ward, Eric Gaukel, Brian Gilger; SCY-641 - A Water-Soluble Cyclophilin Inhibitor for the Treatment of Dry Eye Disease. Invest. Ophthalmol. Vis. Sci. 2011;52(14):4324.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To identify a water soluble cyclosporine derivative with good immunomodulatory properties and ocular distribution profile consistent with treating dry eye disease.
New semi-synthetic derivatives of cyclosporine A were prepared and tested for immunosuppressive potential (inhibition of IL-2 from stimulated Jurkat T-cells) and anti-cytokine activity (inhibition of TNF, IL-1 from corneal epithelial cells). The solubility of new compounds in water, and water/excipient mixtures, was measured by shake-flask methods with HPLC analysis. The ocular distribution of lead compounds was determined by topical administration to rabbits followed by measurement of corneal and conjunctival tissue concentrations.
SCY-641 was identified as a potent inhibitor of cytokine production by stimulated corneal epithelial cells (TNF, IL-1 IC50 0.6, 11 uM) and T-cells (IL-2 IC50 0.04 uM), and to be immunosuppressive in a mixed lymphocyte proliferation assay (EC50 0.2 uM) . The solubility of SCY-641 in water, PEG/water and carboxymethylcellulose/water (0.17, 0.24, and 0.3 mg/mL) was 10-30 fold higher than corresponding values for cyclosporine A. A clear solution of SCY-641 (0.3 mg/mL, 0.03%) in a CMC/water vehicle, autoclaved to achieve sterility, was found to be stable over several months. Topical administration of a 0.03% SCY-641 solution (0.05 mL, q15minX4) to rabbit eyes was well tolerated (slit lamp microscopy, Shaddock-McDonald scoring) and resulted in corneal and conjunctival concentrations (2000 and 2100 ng/g tissue respectively) above the anticipated therapeutic range.
SCY-641 is a new cyclosporine derivative with good immunosuppressive, and anti-cytokine, activity and notably improved aqueous solubility. SCY-641 is readily taken into rabbit corneal and conjunctival tissue following topical application and warrents further evaluation as an alternative treatment for Dry Eye disease.
This PDF is available to Subscribers Only